Format

Send to

Choose Destination
Anticancer Res. 2014 Apr;34(4):1893-9.

Piperine enhances the efficacy of TRAIL-based therapy for triple-negative breast cancer cells.

Author information

1
Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. byosei@inm.u-toyama.ac.jp.

Abstract

BACKGROUND/AIM:

Triple-negative breast cancer (TNBC) is most the aggressive type of breast cancer and is poorly responsive to endocrine therapeutics; however, one of the most attractive treatments is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based therapies. To identify compounds that enhance the efficacy of TRAIL-based therapies, we screened 55 compounds from natural products in combination with TRAIL in TNBC cells.

MATERIALS AND METHODS:

Human TNBC cells, MDA-MB-468 and MDA-MB-231, and murine TNBC cells, 4T1, were used. Cell viability, apoptotic cells, and cell cycle were quantified by the WST-1 assay, annexin-V/7-amino-actinomycinD (7-AAD) staining and Propidium iodide (PI) staining, respectively. In vivo effects of piperine were evaluated in the orthotopic-inoculated 4T1-luc mouse model.

RESULTS:

After screening, we identified piperine as the most potent adjuvant at enhancing the efficacy of TRAIL-based therapies in TNBC cells in vitro and in vivo, which might be mediated through inhibition of survivin and p65 phosphorylation.

CONCLUSION:

Piperine may enhance TRAIL-based therapeutics for TNBC.

KEYWORDS:

TRAIL; Triple-negative breast cancer; apoptosis; piperine

PMID:
24692724
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center